Parkinson’s Vax Enters Clinical Trials

Posted: Published on June 8th, 2012

This post was added by Dr Simmons

Researchers in Vienna are starting a Phase I trial on the first ever vaccine with a potential to treat the neurodegenerative disease.

By Bob Grant | June 7, 2012

Alpha-synuclein accretions (brown spots) accumulate in the brains of Parkinson's patientsWikimedia Commons, Jensflorian

A new vaccine that has the potential to treat Parkinsons disease is entering a Phase I clinical trial in Vienna. The first-of-its-kind vaccine, PD01A, aims to ramp up an immune response to the alpha-Synuclein (alpha-syn) protein, which is involved in the onset and progression of Parkinsons. Austrian biotech AFFiRiS is testing the vaccine with support from the Michael J. Fox Foundation.

Worldwide, for the first time immunotherapy is applied for the treatment of Parkinsons, AFFiRiS CEO Walter Schmidt said in a statement. PD01A is the first medication worldwide aiming for clinical efficacy by modulating the metabolic pathway of alpha-syn.

Hat tip to Medical News Today.

By Cristina Luiggi

The regulatory agency will allow early-stage breast cancer patients to try experimental drugs previously reserved for those with advanced disease.

By Bob Grant

A genetic testing company fields concerns that their latest gene patent goes against their core beliefs regarding access to genetic information.

Read more from the original source:
Parkinson’s Vax Enters Clinical Trials

Related Posts
This entry was posted in Parkinson's Treatment. Bookmark the permalink.

Comments are closed.